Researchers at Graz University of Technology (TU Graz) have developed a virtual reality (VR) system that could enable more personalized and precise treatment of arachnophobia. The prototype, called VRSpi, combines VR exposure therapy with real-time physiological monitoring to adjust treatment intensity based on a patient’s stress level.
Exposure therapy is widely used to treat phobias by gradually confronting patients with fear-inducing stimuli. Virtual Reality Exposure Therapy (VRET) is increasingly applied as a safe and scalable alternative to real-life exposure. However, current approaches typically rely on therapists’ subjective assessment to determine the intensity of exposure. The study was published in Frontiers in Human Neuroscience.
Data-driven alternative
The VRSpi system introduces a data-driven alternative by continuously analyzing electroencephalography (EEG) signals and heart rate. Based on these objective measurements, the system dynamically adapts the virtual environment to match the user’s anxiety level, helping to avoid both overstimulation and insufficient exposure.
“The brain waves and heart rate provide us with reliable indications of how much stress someone is currently experiencing,” says Selina Wriessnegger of TU Graz. In particular, changes in frontal alpha asymmetry in EEG data were found to correlate with anxiety levels.
Real-time adaptation in VR
In a feasibility study, 21 participants were exposed to virtual spiders of varying size and number while wearing EEG caps and VR headsets. The system analyzed brain activity in real time and adjusted the intensity of the stimuli accordingly.
The results showed a clear relationship between increasing anxiety and activity in the right frontal lobe of the brain. According to the researchers, this demonstrates that anxiety can be reliably measured and used to control virtual environments in a personalized way.
“Our results show that anxiety can be reliably measured in the brain and that the data can be used for adaptive control of virtual environments,” says Wriessnegger. “This opens up new possibilities for personalized treatment concepts in which the exposure is dosed precisely and individually.”
Clinical adoption
Despite promising results, the researchers note that hardware remains a barrier to wider clinical implementation. Current systems rely on EEG caps, which are not user-friendly and require trained personnel. More compact alternatives, such as wearable or in-ear EEG devices, are under development but currently do not yet match the measurement accuracy of traditional systems.
The researchers suggest that further technological advances could help translate neuroadaptive VR systems into routine clinical practice, potentially improving outcomes for patients with anxiety disorders.
VR reduces fear of death
Earlier this year, researchers at Texas A&M University have shown that immersive virtual reality (VR) may help reduce fear of death. In a pilot study involving young adults, a single 12-minute VR session led to a 75% reduction in reported fear of death. The study, published in Frontiers in Virtual Reality, examined a simulated near-death experience that guided participants through various phases, including an out-of-body experience and a reflective environment.
Afterward, most participants reported less stress and a more positive outlook on life. VR could thus be a valuable addition to digital mental health care, for example within telehealth. At the same time, the researchers emphasize that caution is needed, as a small number of participants actually experienced increased anxiety. Further studies are needed to confirm the effectiveness and safety in broader patient groups.
